Five key insights into 2020’s drug royalty transactions

Providing additional opportunities for the monetisation of life sciences IP, the drug royalty market continued to develop in 2020, producing a slew of new deals with creative and flexible structures

Enter your details below to log into your account.

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Twitter

05 Aug 2021

@IAM_Alerts Ray Millien has left his his job as chief IP officer of Volvo cars to become CEO of @HarnessDickey. He spoke exclus… https://t.co/iSnKi2X0Ui Read more

05 Aug 2021

@IAM_Alerts Following Royalty Pharma’s ground-breaking IPO, Healthcare Royalty’s offering is further proof of the growth of a m… https://t.co/wr91oieYJA Read more

04 Aug 2021

@IAM_Alerts RT @AMorrisReports: Read my interview with Judge Albright from earlier this week where he talks about the circuit's message about his handl… Read more

04 Aug 2021

@IAM_Alerts The Long Read: Everything you wanted to know about patent rescue in Europe, but were too afraid to ask… https://t.co/i5R9TxId00 Read more

Find an expert

Claudio Ulloa

Partner

Mexico City, Mexico

Basham, Ringe y Correa SC

View full biography

Five key insights into 2020’s drug royalty transactions

Returning user?

Want to read more?

Adam Houldsworth

TAGS

Twitter

Find an expert